C000203168 Fees and Costs — EQ/T. Rowe Price Health Sciences Portfolio, Class IB
Data updated: 2026-08-25
The net expense ratio is 1.20%: a 0.95% management fee, a 0.25% 12b-1 fee plus 0.17% other expenses, less a 0.17% fee waiver. There are no sales loads or redemption fees. In fiscal 2025 the fund paid $46K in broker commissions, 0.0287% of average net assets, and portfolio turnover was 42%.
C000203168 Fees and Expenses
Annual operating expenses and sales charges of C000203168. Prospectus, as of April 30, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.95% |
| 12b-1 fee | 0.25% |
| Other expenses | 0.17% |
| Gross expense ratio | 1.37% |
| Fee waiver | −0.17% |
| Net expense ratio | 1.20% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | Yes |
C000203168 Costs Over Time
On $10,000 invested in C000203168, assuming 5% a year before costs, total costs come to $765 over 5 years, cutting the return by 1.29% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 1.20%) | $126 | $392 | $679 |
| Trading costs (broker commissions) | $3 | $9 | $16 |
| Lost growth on money paid in costs | $0 | $20 | $70 |
| Total costs | $129 | $421 | $765 |
| Value after costs | $10,371 | $11,155 | $11,998 |
| Impact on return, per year | 1.29% | 1.29% | 1.29% |
C000203168 Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.0287%
- Total broker commissions: $46K
- Bought from dealers (principal trades, not a cost): $4.0M
- Portfolio turnover (prospectus): 42%
- Securities on loan, average value: $4.5M
- Net income from securities lending: $65K (0.040% of average net assets)
C000203168 Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Jefferies LLC | $4K | 15.07% |
| UBS Securities LLC | $3K | 11.49% |
| Morgan Stanley & Co. LLC | $3K | 11.19% |
| RBC Capital Markets, LLC | $3K | 11.09% |
| BofA Securities, Inc. | $3K | 10.01% |
| Goldman Sachs & Co. LLC | $3K | 9.48% |
| TD SECURITIES (USA) LLC | $2K | 8.64% |
| J.P. Morgan Securities LLC | $2K | 8.04% |
| Virtu Americas LLC | $2K | 8.00% |
| Citigroup Global Markets Inc. | $2K | 7.00% |
C000203168 Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| Jefferies LLC | $1.1M | 26.10% |
| Leerink Partners LLC | $785K | 19.48% |
| J.P. Morgan Securities LLC | $606K | 15.04% |
| Goldman Sachs & Co. LLC | $598K | 14.85% |
| Morgan Stanley & Co. LLC | $485K | 12.04% |
| Piper Sandler & Co. | $179K | 4.44% |
| BofA Securities, Inc. | $146K | 3.63% |
| CGS - CIMB Securities (USA), Inc. | $99K | 2.46% |
| TD SECURITIES (USA) LLC | $64K | 1.58% |
| H.C. WAINWRIGHT & CO., LLC | $15K | 0.37% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.